This presentation takes a closer look at a critical time within the prostate cancer disease journey between the localized and advanced disease state. Metastasis, when the cancer spreads to a different part of the body, is currently targeted by multiple treatment options available in the market. With the recent SPARTAN and PROSPER clinical trials, there are new drug developments that may target the non-metastatic castration resistant prostate cancer window to further delay metastases. Key tools and imaging options in detecting metastases are also discussed.
SPEAKER: Dr. Robert Hamilton is an uro-oncologic surgeon specializing in prostate cancer at the Princess Margaret Cancer Centre. He has expertise in minimally invasive surgeries, including robotic surgery. Dr. Hamilton sees patients at all different stages of prostate cancer from those at risk to this with early diagnoses to advanced disease. His research interests in prostate cancer include the study of statins and metformin in prostate cancer prevention; whether genetic markers can be used to predict who will benefit from chemoprevention; and biomarkers of prostate cancer aggressiveness.
DATE: Thursday, March 29, 2018
JOIN NOW: https://bit.ly/2pSb0mf